hVIVO CEO Yamin ‘Mo’ Khan presenting in-person at the Jefferies Healthcare Conference

hVIVO plc
[shareaholic app="share_buttons" id_name="post_below_content"]

hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that Yamin ‘Mo’ Khan, Chief Executive Officer, will be presenting in-person at the Jefferies Healthcare Conference in London on 19 November 2024 at 12:00pm GMT. Alongside the presentation, the Company will also be available for one-to-one meetings.

The Jefferies Conference is the largest healthcare-dedicated conference in Europe. The conference hosts over 650 healthcare companies, 3,000 attendees, and nearly 8,000 investor and business-to-business meetings. The conference will feature leading public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors from the Americas, Europe, Middle East, Africa, Asia, and Australia.

hVIVO is a fast-growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
hVIVO plc, a leader in human challenge trials, announces positive results for Enanta Pharmaceuticals' RSV antiviral candidate EDP-323 in a recent study.
hVIVO plc (LON:HVO), a leading CRO in infectious and respiratory disease research, will release its interim results for H1 2024 on 10 September 2024.
hVIVO plc (LON:HVO), a leading CRO specializing in infectious and respiratory disease products, reports a robust 30.6% revenue growth for H1 2024, driven by strong operational performance.
hVIVO to conduct a major Phase 2b field study on an influenza drug, enrolling 1,000 volunteers at its expanded Plumbers Row site, supporting future growth.

Search

Search